Every S-3 that Elicio Therapeutics, Inc. (ELTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow ELTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTX filings page.
Elicio Therapeutics is registering up to $400,000,000 of securities on a shelf to be sold from time to time, consisting of common stock, preferred stock, debt securities, warrants and units.
The pre-effective amendment updates the prospectus to incorporate the Company’s Annual Report on Form 10-K filed March 12, 2026, revises the Risk Factors and Experts sections, refreshes the corporate overview and forward-looking statements, and files the independent auditors’ consent as Exhibit 23.1. The prospectus states net proceeds will be used for working capital, research and development, business expansion, strategic transactions and general corporate purposes, with specific terms to be provided in prospectus supplements. The filing also notes recent clinical program context: the Phase 2 AMPLIFY-7P study of ELI-002 7P continued to final analysis after an IDMC interim review and the company anticipates a final disease-free survival analysis in the first half of 2026. The Company’s common stock traded at $12.90 on Nasdaq on March 10, 2026.
Elicio Therapeutics, Inc. filed Pre-Effective Amendment No. 1 to its registration statement (S-3/A) to delay the registration statement’s effective date by including the cover-page delaying amendment language.
The amendment states it does not modify the prospectus, includes an expenses table showing a SEC registration fee of $55,240.00 and a FINRA filing fee of $60,500.00, and describes indemnification provisions under Delaware law, the company’s charter and bylaws, director and officer indemnification agreements, a six-year indemnity/anti-amendment covenant tied to a Merger Agreement, and a six-year prepaid tail D&O policy.
Elicio Therapeutics, Inc. filed a shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units, to be sold from time to time February 27, 2026.
The prospectus describes that specific terms, pricing and offering methods will be set forth in future prospectus supplements; the company noted its common stock trades on Nasdaq at $11.74 per share as of February 26, 2026.
Elicio Therapeutics (ELTX) filed a resale registration covering up to 103,225 shares of common stock, issuable upon exercise of a warrant issued on June 3, 2025 to GKCC, LLC. The company will not receive proceeds from any sales by the selling stockholder; it may receive cash proceeds only if the warrant is exercised. The warrant is immediately exercisable, expires five years from issuance, and has a $7.75 per share exercise price, subject to a 49.99% beneficial ownership cap.
The selling stockholder may sell shares from time to time through public or private transactions at market or negotiated prices, using methods listed in the plan of distribution, including short sales after the registration statement is declared effective. ELTX trades on Nasdaq; the last reported sale price was $9.19 on November 12, 2025. As context, shares outstanding were 17,413,843 as of October 31, 2025; this is a baseline figure, not the amount being offered.